SPOTLIGHT: BMS a takeover target?

BMS a takeover target?
Analysts are salivating over Bristol-Myers Squibb. Healthy earnings and sales growth, coupled with a stock price down by about a third since last July, makes the drug maker "an attractive takeover candidate for a larger pharma," according to a Zacks Investment Research analyst. Report